Amneal strikes $1.1B deal for Kashiv to build an integrated biosimilars platform
What’s the deal? Amneal Pharmaceuticals (Nasdaq: AMRX) has agreed to acquire Kashiv BioSciencesDealroom has a profile for this one. Try Dealroom → for up to $1.1B — $375M in cash, $375M in equity, and up to $350M in contingent milestone payments. The deal creates what Amneal calls a “fully integrated global biosimilar platform.” Closing is expected in the second half of 2026.
The two companies are not strangers. Amneal co-chief executives Chintu PatelDealroom has a profile for this one. Try Dealroom → and Chirag PatelDealroom has a profile for this one. Try Dealroom → directly or indirectly own half of Kashiv. The companies have collaborated since 2017, when Amneal licensed biosimilar copies of Amgen’s Neulasta and Neupogen from Kashiv. Both won FDADealroom has a profile for this one. Try Dealroom → approval in 2022.
Why now? More than $300B of global biologics are expected to lose patent exclusivity over the next decade. The biosimilar market is approaching an inflection point, and Amneal is betting that vertical integration — owning development, manufacturing, and commercialisation — is the way to capture it.
Kashiv brings four manufacturing facilities: a Chicago plant with fill-finish capabilities, a New Jersey site with 6,000 litres of monoclonal antibody capacity, and two plants in India. Amneal plans to scale drug substance capacity from 26,000 litres in 2026 to 75,000 by 2028, with $30–50M a year in capital expenditure.
The combined pipeline is substantial. Six biosimilars could launch by next year, with another six targeting a $42B addressable market from 2028 to 2030. That includes copies of Merck’s Keytruda (~$20B opportunity) and Eli Lilly’s Trulicity (~$10B). Amneal aims to deliver three to five biosimilar launches per year.
What could go wrong? The Patel brothers’ ownership of both buyer and target is a governance question. Amneal says the deal was negotiated at arm’s length, but the structure — equity plus milestones flowing to founders who sit on both sides — invites scrutiny.
Biosimilar manufacturing at scale is technically demanding. Scaling from 26,000 to 75,000 litres in two years is ambitious, and execution risk on the Keytruda and Trulicity programmes is high. Each biosimilar also faces its own regulatory and patent challenge timeline.
Amneal expects $400–500M in financial synergies, largely from eliminating milestone and royalty obligations. That is a significant portion of the deal value and assumes successful biosimilar launches hit their targets.
The signal: The biosimilar market is entering its biggest growth phase. As biologics lose exclusivity, companies that control the full value chain — from cell line development to commercial distribution — will have structural advantages over those relying on contract manufacturers or licensing partners.
Amneal reported $723M in Q1 2026 revenue (+4% year-on-year) and $202M in adjusted EBITDA (+19%), raising its full-year guidance alongside the deal announcement. The acquisition is a bet that biosimilars will be the growth engine that carries the company into the next decade.
Sources:
GlobeNewsWire (Amneal press release)
BusinessWire (Kashiv press release)
Reuters
Fierce Pharma
BioSpace
BioPharm International
Image credit:
Amneal Pharmaceuticals
J.V.
